根治性前列腺切除术后生化复发时高百分比游离PSA与较差结局相关:基于前瞻性生物样本库标本的验证研究
本研究利用前瞻性收集的生物样本库标本,验证根治性前列腺切除术后生化复发时百分比游离前列腺特异性抗原(%fPSA)≥15%是否与更具侵袭性的疾病相关。共纳入154例患者,%fPSA≥15%者28例(18%)。结果显示%fPSA≥15%与更早接受雄激素剥夺治疗、更早发生转移和去势抵抗显著相关。
要点
- %fPSA≥15%组接受ADT风险显著增高(43% vs 25%,调整HR 2.40)。
- %fPSA≥15%组转移风险显著增高(21% vs 7.9%,调整HR 4.10)。
- 生化复发时%fPSA≥15%提示更具侵袭性疾病,与诊断场景相反。
核心结论
- 根治性前列腺切除术后生化复发时%fPSA≥15%是更具侵袭性疾病的指标,预示更早启动ADT、更早进展至去势抵抗和转移。
研究设计与样本
- 验证性研究,使用前瞻性收集的生物样本库标本,纳入根治性前列腺切除术后PSA不可测随后生化复发(PSA≥0.1 ng/ml)的患者154例。
主要发现
- %fPSA≥15%组28例(18%),%fPSA<15%组126例(82%);中位随访分别为69个月和75个月。
- %fPSA≥15%组接受ADT比例为43% vs 25%(调整HR 2.40,95%CI 1.12-5.11)。
- %fPSA≥15%组转移比例为21% vs 7.9%(调整HR 4.10,95%CI 1.11-15.2)。
- %fPSA≥15%组去势抵抗性前列腺癌比例为14% vs 4.0%(未调整HR 4.14,95%CI 1.11-15.5)。
关键数值与推荐
- 生化复发定义为根治性前列腺切除术后PSA≥0.1 ng/ml。
- %fPSA cutoff值为15%,≥15%为高%fPSA组。
临床怎么用
- 根治性前列腺切除术后生化复发时检测%fPSA有助于识别更具侵袭性疾病风险的患者。
- %fPSA≥15%提示需更密切监测,可能更早需要ADT等干预。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The role of percent free prostate specific antigen (%fPSA) in patients who have undergone radical prostatectomy and subsequently experienced disease relapse is unclear. We previously conducted 2 retrospective studies and found %fPSA 15 or greater in the setting of biochemical recurrence confers more aggressive disease. To validate that finding we used biobank specimens collected prospectively when patients were first diagnosed with biochemical recurrence. MATERIALS AND METHODS: Biobank specimens of patients with undetectable prostate specific antigen after radical prostatectomy and subsequent biochemical recurrence (prostate specific antigen 0.1 ng/ml or greater) were analyzed for %fPSA. Patients were stratified according to the %fPSA cutoff of 15. Univariable and multivariable logistic regression analysis was performed to predict covariates associated with a higher %fPSA. Cox proportional hazard models were performed to evaluate the prognostic effect of %fPSA on androgen deprivation therapy-free survival, metastasis-free survival, castration resistant-free survival and cancer specific survival. RESULTS: A total of 154 men were included in the study, of whom 126 (82%) had %fPSA less than 15 and 28 (18%) had %fPSA 15 or greater. Median followup for %fPSA less than 15 and %fPSA 15 or greater was 75 and 69 months, respectively. Patients with %fPSA 15 or greater had increased hazard of receiving androgen deprivation therapy (43% vs 25%, adjusted HR 2.40, 95% CI 1.12-5.11), metastatic disease (21% vs 7.9%, adjusted HR 4.10, 95% CI 1.11-15.2) and castration resistant prostate cancer (14% vs 4.0%, unadjusted HR 4.14, 95% CI 1.11-15.5) vs %fPSA less than 15, respectively. CONCLUSIONS: Patients with %fPSA 15 or greater were started on androgen deprivation therapy earlier, and they had progression to castration resistant prostate cancer and metastatic stage earlier. %fPSA 15 or greater in the setting of biochemical recurrence after radical prostatectomy is an indicator of a more aggressive disease. Unlike in the diagnostic setting, a higher %fPSA portends a worse clinical outcome.
引用
- Woon DTS, Herrera-Cáceres JO, Goldberg H, et al. A High Percent Free Prostate Specific Antigen in the Setting of Biochemical Recurrence after Radical Prostatectomy is Associated with Poorer Outcomes: A Validation Study Using Prospectively Collected Biobank Specimens. J Urol. 2020. PMID: 32068483. doi:10.1097/JU.0000000000000808
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。